Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood enzyme reveal who will survive deadly shock?

NCT ID NCT06539234

Knowledge-focused Sponsor: University Medical Centre Maribor Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Vasoplegic shock is a life-threatening drop in blood pressure that can lead to organ failure. Doctors at University Medical Centre Maribor are studying patients whose blood pressure stays too low despite standard drugs. They measure renin, an enzyme tied to blood pressure regulation, before and six hours after starting synthetic angiotensin II. The goal is to see whether renin changes predict who recovers faster and who benefits most from this treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
synthetic angiotensin II, a hormone drug that raises blood pressure
What this could lead to
If renin levels predict who responds, doctors could choose angiotensin II earlier for the right patients and avoid it for those unlikely to benefit.
What could go wrong
This is an observational study at a single centre, so it can show a link between renin and outcomes but cannot prove that renin testing improves care. Results may not apply to other hospitals or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 121 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients (≥ 18 years old) with distributive shock (\<72 hours duration) regardless of etiology without limitations for treatment and a predicted survival \>24 hours.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients with distributive shock lasting \< 72 hours * a goal mean arterial pressure (65-85 mmHg) not achieved despite optimal fluid resuscitation (30 ml/kg cristalloid) and an infusion of at least noradrenaline 0.3 mcg/kg/min and vasopressin 0.03 IE/min * the patient did not get angiotensin II before * predicted survival is \>24h * no limitations for active treatment Exclusion Criteria: * burns \>20% body area * acute coronary syndrome * bronchospasm * liver disease (MELD ≥30) * severe acute bleeding (need for 4 or more units of concentrated erythrocyte) * acute mesenteric ischemia * aortic dissection * leucopenia \<1000/mm3 * pregnancy * Raynaud disease, systemic sclerosis, vasospastic disease * active venous or arterial thromboembolic disease * the need for daily dose of hydrocortisone 500 mg or more * ECMO * cardiac index \<l/min/m2 (defined by echocardiography or invasive methods) * central venous oxygen saturation (SCVO2) \>70%

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Shock are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Shock toxic shock syndrome Vasoplegia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Shock Vasoplegic syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Medical ICU, University Medical Centre Maribor

    RECRUITING

    Maribor, 2000, Slovenia

  • Surgical ICU, University Medical Centre Maribor

    RECRUITING

    Maribor, 2000, Slovenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.